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ABSTRACT: Magnetic, antimicrobial-carrying nanoparticles provide a promising, new and direly needed antimicrobial
strategy against infectious bacterial biofilms. Penetration and accumulation of antimicrobials over the thickness of a biofilm is a
conditio sine qua non for effective killing of biofilm inhabitants. Simplified schematics on magnetic-targeting always picture
homogeneous distribution of magnetic, antimicrobial-carrying nanoparticles over the thickness of biofilms, but this is not easy to
achieve. Here, gentamicin-carrying magnetic nanoparticles (MNPs-G) were synthesized through gentamicin conjugation with
iron-oxide nanoparticles and used to demonstrate the importance of their homogeneous distribution over the thickness of a
biofilm. Diameters of MNPs-G were around 60 nm, well below the limit for reticuloendothelial rejection. MNPs-G killed most
ESKAPE-panel pathogens, including Escherichia coli, equally as well as gentamicin in solution. MNPs-G distribution in a
Staphylococcus aureus biofilm was dependent on magnetic-field exposure time and most homogeneous after 5 min magnetic-field
exposure. Exposure of biofilms to MNPs-G with 5 min magnetic-field exposure yielded not only homogeneous distribution of
MNPs-G, but concurrently better staphylococcal killing at all depths than that of MNPs, gentamicin in solution, and MNPs-G,
or after other magnet-field exposure times. In summary, homogeneous distribution of gentamicin-carrying magnetic
nanoparticles over the thickness of a staphylococcal biofilm was essential for killing biofilm inhabitants and required optimizing
of the magnetic-field exposure time. This conclusion is important for further successful development of magnetic, antimicrobial-
carrying nanoparticles toward clinical application.
KEYWORDS: magnetic targeting, magnetic nanoparticles, gentamicin, biofilm, infection
Development of new infection-control strategies isbecoming more and more urgent. Antimicrobial-resistant
bacterial infections have been predicted to become the number
one cause of death in the year 2050, exceeding the number of
deaths caused by cancer.1 New infection-control strategies
should not only evade rapidly arising bacterial antimicrobial-
resistance mechanisms,2 but preferentially also self-target
infectious biofilms and achieve homogeneous distribution of
an antimicrobial over the entire thickness of a biofilm.
However, such a homogeneous distribution is hard to achieve.
Antimicrobials, even when applied to antimicrobial-susceptible
strains, solely kill those bacteria that reside on the outer part of
a biofilm.3 As a result, many infections are recurrent, which
increases the chances of development of antimicrobial
resistance.4 Hopes are high that nanotechnology will
contribute to the development of new infection-control
strategies,5 for which self-targeting, pH-adaptive antimicrobial
micelles, liposomes, or polymersomes, antimicrobial carbon
dots and dendrimers, and photothermal and magnetic
antimicrobial nanoparticles have all been considered “promis-
ing”.
Magnetic targeting of drugs is considered promising as a
new infection-control strategy and in tumor treatment, as it
allows one to establish high drug concentrations at the target
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site.6,7 Magnetic targeting of drugs requires two trivial
components: drug-carrying magnetic nanoparticles and a
magnet-targeting system. Magnetic targeting of micrometer-
sized infections is arguably more difficult, especially in vivo,
than the targeting of much larger tumors. It is frequently
assumed,8−12 that magnetic, antimicrobial nanoparticles fully
penetrate and distribute homogeneously over the thickness of a
biofilm under the influence of a magnetic field (see Figure 1).
Usually, however, particularly in vivo, this is not easy and even
targeting of magnetic, antimicrobial nanoparticles to a biofilm
site, as opposed to homogeneous distribution over the
thickness of a biofilm, requires sophisticated instrumentation.13
Current magnetic targeting instrumentation is not suitable
to distribute magnetic nanoparticles homogeneously through a
biofilm, considering that most clinical biofilms have a thickness
limited to 200 μm.14 A wireless magnetic targeting system has
been described for precise control of cylindrical “microrobots”
through the posterior segment of the eye for surgical
procedures and drug delivery.15 However, these microrobots
had dimensions (1800 × 285 μm2), exceeding the dimensions
of nanoparticles by far. A similar objection holds for the
magnetic targeting of nanoparticles as an antimicrobial
dispersant of biofilms, requiring nanoparticles with a diameter
of 213 nm for targeting,16 above the critical limit of 200 nm for
reticuloendothelial rejection.17−19
New technologies for infection-control need to be simple,
however, and allow precise control over smaller nanoparticles
(<200 nm) over more micrometer-sized dimensions, if
downward clinical translation of antimicrobial, magnetically
targetable nanoparticles is the goal.20,21 Also, translation to
clinical use will become more likely when new treatment
modalities build on conventional ones. Therefore, we recently
proposed to use simple, magnetic, non-antimicrobially
functionalized nanoparticles to create artificial water channels
in infectious biofilms by magnetically induced movement of
nanoparticles to make biofilms more penetrable and
susceptible to conventional antibiotic treatment.22 Artificial
channel digging does not require any accumulation or precise
control or homogeneous distribution of nanoparticles inside
the biofilm.
Here, we created magnetic, antimicrobial-carrying nano-
particles, with the aim of demonstrating the difficulty in
achieving homogeneous distribution of magnetic, antimicrobial
nanoparticles and bacterial killing across the thickness of a
biofilm. A simple methodology to achieve homogeneous
distribution of magnetic, gentamicin-carrying nanoparticles
across the thickness of an infectious biofilm growing on a
biomaterial surface was developed and demonstrated to be
accompanied by enhanced killing of biofilm inhabitants.
Biomaterial-associated infections are a special class of
recalcitrant infections, caused by bacteria forming an infectious
biofilm on biomaterials implants and devices, such as total hip
or knee arthroplasties, heart valves, vascular grafts, and many
other types of implants and devices.20,23
First, gentamicin (G), a commonly used aminoglycoside
with a wide spectrum of antibacterial activity and particularly
suitable for local application,24 was conjugated through its
amino groups to the carboxyl groups on the surface of an iron
oxide, magnetic nanoparticle (MNP) using peptide coupling
(Figure 2a).25 Effective conjugation of G to MNPs was
demonstrated from the presence of characteristic G- and
peptide-coupling bands in Fourier transform infrared (FTIR)
spectra (Figure 2b), i.e., the bands at 1400, 1575, and 1650
cm−1 due to the stretching of N−H, C−N, and CO of the
peptide coupling and the band at 1030 cm−1 attributed to the
C−O−C stretching of G. Zeta potentials of MNPs were highly
negative (−38.8 ± 2.1 mV; see Figure 2c) due to their
carboxyl-rich surface and became positive (8.8 ± 0.2 mV) after
G-conjugation26 as a result of amino-groups in gentamicin.
Magnetic properties of MNPs-G (43.4 emu g−1; see Figure 2d)
were only slightly lower than those of MNPs (46.8 emu g−1).
Thermogravimetric and elemental analysis indicated that G-
conjugation in MNPs-G amounted to 24−25% by mass
(Figure 2e and f, respectively). The diameter of MNPs-G as
obtained using transmission electron microscopy (TEM) was
around 60 nm (Figure 2g).
MNPs-G had a broad antibacterial activity against a variety
of pathogen members from the so-called ESKAPE-panel,27
Enterobacter cloacae BS 1037, Staphylococcus aureus ATCC
12600, Klebsiella pneumonia-1, Acinetobacter baumannii-1,
Pseudomonas aeruginosa PA01, and Enterococcus faecalis 1396
with the exception of K. pneumonia and A. baumannii (Figure
3a). In addition to ESKAPE-panel pathogens, MNPs-G were
also antibacterially active against E. coli ATCC 25922. In
general, MBCs of MNPs-G were slightly but significantly lower
than of gentamicin. This is likely because electrostatic double-
layer attraction between negatively charged bacteria28 and
positively charged MNPs-G demonstrates that conjugation did
not negatively impact the antibacterial properties of
gentamicin. Growth of mouse fibroblasts with MNPs-G did
not negatively impact the metabolic activity of the cells (Figure
3b), while bare magnetic iron oxide nanoparticles were fully
Figure 1. Simplified schematics of magnetic, antimicrobial nanoparticle penetration into an infectious biofilm. (a) The biofilm mode of bacterial
growth on a surface prevents penetration of magnetic nanoparticles into an infectious biofilm, and in the absence of a magnetic field magnetic,
antimicrobial nanoparticles can solely kill bacteria at the outside of the biofilm. This is the common scenario for antimicrobial penetration in a
biofilm.3 (b) External magnetic fields are frequently pictured to facilitate deep penetration of magnetic nanoparticles into infectious biofilms, while
assuming rather than experimentally demonstrating homogeneous distribution of magnetic, antimicrobial nanoparticles across the entire thickness
of a biofilm under an applied magnetic-field as trivial.8−12
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biocompatible with these mammalian cells, as shown
previously.29 This is in line with the known biocompatibility
of iron oxide nanoparticles to mammalian cells.17,30 Moreover,
iron oxide nanoparticles are known to be removed from the
body through phagocytosis.31
Red-fluorescent Rhodamine-B isothiocyanate labeled MNP-
G showed a clear depth-dependent distribution of nano-
particles in S. aureus biofilms upon magnetic targeting (Figure
4a). After 3 h, upon short magnetic-field exposure (1 and 2
min), nanoparticles accumulated predominantly near the top
of the biofilm, while after 5 min an even distribution across the
thickness of the biofilm could be observed. Longer magnetic-
field exposure times yielded nanoparticle depletion of the
suspension and accumulation of the nanoparticles near the
substratum surface, i.e., in the bottom region of the biofilm. In
absence of magnetic-field exposure, MNPs-G did not penetrate
in the biofilm, and not after prolonged exposure times.
In order to establish a direct relation between MNP-G
penetration and staphylococcal killing in biofilms, an identical
experiment was carried out in absence of Rhodamine labeling
of MNPs-G, but this time staining the bacteria with green-
fluorescent SYTO9 and red-fluorescent propidium iodide to
distinguish live and dead bacteria, respectively.10 The number
of live (green-fluorescent) and dead (red-fluorescent) bacteria
was determined from the confocal laser scanning microscopy
(CLSM) images, using ImageJ to quantify the number of
Figure 2. Preparation and characterization of magnetic, gentamicin-carrying nanoparticles (MNPs-G). (a) Synthesis of MNPs-G. The carboxyl
(−COOH) group of the carboxyl-functionalized MNP is conjugated with the one of the amino (−NH2) groups on gentamicin through a peptide-
coupling, using 1-(3-(dimethylamino)propyl)-3-ethylcarbodiimide hydrochloride (EDC) and N-hydroxy succinimide (NHS) as catalysts. The
reaction occurs at room temperature. (b) Fourier transform infrared (FTIR) spectra of G, MNPs, and MNPs-G. (c) Zeta potentials of MNP before
and after conjugation of gentamicin in water (pH 7.0). (d) Magnetic hysteresis loops at 300 K for MNPs before and after conjugation of
gentamicin, measured by vibrating sample magnetometry. Inset in the lower right corner shows the magnetic behavior of MNPs-G under an applied
external magnetic-field. (e) Thermogravimetric analysis of G, MNPs, and MNPs-G. The percent of weight loss over the temperature range between
210 and 490 °C was applied to calculate the weight percent of gentamicin in MNPs-G. (f) Elemental analysis of G, MNPs, and MNPs-G. Nitrogen
(N) is absent in MNPs but present in G and MNPs-G, from which it can be concluded that the weight increase of MNPs-G compared to MNPs
(panel e) is due to G. Data are expressed as mean ± standard deviation over three separate measurements. (g) TEM micrograph of the MNPs-G as
synthesized in this study.
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green- and red-fluorescent bacteria. The distribution of dead
bacteria across the thickness of a biofilm roughly followed the
same distribution pattern as of MNPs-G (compare Figure 4a
and b). Shorter magnetic-field exposure times yielded more
dead bacteria near the top of the biofilm, while longer exposure
times also caused bacterial death in the bottom of the biofilm.
However, the total number of MNPs-G accumulated in a
biofilm related well with the number of dead staphylococci
over the entire thickness of a biofilm (Figure 4c). This attests
to the importance of penetration and homogeneous accumu-
lation of antimicrobial-carrying nanoparticles for killing
bacteria in a biofilm mode of growth. Figure 4a and b yields
the conclusion that deep killing of biofilm inhabitants requires
good penetration of antimicrobial, magnetic nanoparticles in
the biofilm (Figure 4b) and that overall killing is highest when
antimicrobial nanoparticles distribute homogeneously across
the thickness of a biofilm (Figure 4a and b). For the MNPs
and magnet setup used here, optimal magnet-exposure time
thus equals 5 min.
Finally, using the optimal magnetic-field exposure time of 5
min for deep penetration, killing efficacies of gentamicin,
MNPs, and MNPs-G in the absence and presence of magnetic-
field exposure were evaluated compared with PBS. MNPs in
the presence of magnetic-field exposure yielded a similarly
almost no depth-dependence killing (Figure 5a) and low
biofilm-killing efficacy (Figure 5b) of S. aureus as PBS, while
exposure to G or MNPs-G in the absence of magnetic-field
exposure yielded low depth-dependent killing and biofilm-
killing efficacy. Exposure of staphylococcal biofilms to MNPs-
G in the presence of a magnetic-field for the optimal exposure
time of 5 min, yielded superior staphylococcal killing at all
depths (Figure 5a) and across the entire thickness of the
biofilms (Figure 5b).
In conclusion, this work shows that it should not be a priori
assumed that magnetic-field exposure yields a homogeneous
distribution of magnetic nanoparticles over the entire thickness
of a biofilm as is the commonly assumed scenario in the
current literature.8−12 Too short magnetic-field exposure yields
accumulation of magnetic nanoparticle near the top of a
biofilm, while too long exposure times create more
accumulation near the bottom. Under the conditions applied
in this work, homogeneous distribution of magnetic nano-
particles could be achieved using an intermediate magnetic-
field exposure time of 5 min, but different culturing platforms,
including clinical biofilms, may yield different optimal exposure
times. Homogeneous distribution of magnetic, gentamicin-
carrying nanoparticles achieved after the optimal magnetic-
field exposure time yielded better depth-dependent staph-
ylococcal killing and biofilm-killing efficacy (over an entire
biofilm) than other magnetic-field exposure times. Moreover, a
homogeneous distribution of magnetic, gentamicin-carrying
nanoparticles yielded better killing than gentamicin or
magnetic, gentamicin-carrying nanoparticles in absence of
magnetic-field exposure. Thus, homogeneous distribution of
magnetic, antimicrobial-carrying nanoparticles is a conditio
sine qua non for optimal killing. Clinical translation of the use
of magnetic, antimicrobial-carrying nanoparticles is not trivial,
but it is easiest to achieve for biomaterial-associated infections,
in which the bottom of a biofilm is well-defined, as it concurs
with the surface of the implant or device (i.e., demonstrated in
the current study). In other types of infections, like, e.g., organ
infections, a magnetic field might be placed at multiple angles
toward an infection site to achieve homogeneous distribution
of magnetic, antimicrobial-carrying MNPs in the infectious
biofilm, which we demonstrate here is absolutely needed to kill
biofilm inhabitants over the depth of a biofilm.
■ EXPERIMENTAL SECTION
Materials. Gentamicin, 3,4-dihydroxyhydrocinnamic acid
(DHCA), 1-(3-(dimethylamino)propyl)-3-ethylcarbodiimide hydro-
chloride (EDC), N-hydroxysuccinimide (NHS), 1-octadecene, oleic
acid, sodium oleate, and iron(III) chloride (FeCl3·6H2O) were
purchased from Aldrich. Tetrahydrofuran (THF), ethanol and hexane
were purchased from Sinopharm Chemical Reagent Co. (China). All
chemicals were used as received.
Preparation and Characterizations of Magnetic, Gentami-
cin-Carrying Nanoparticles (MNPs-G). Carboxyl-functionalized,
iron oxide magnetic nanoparticles (MNPs, 10 mg mL−1, 1 mL,
prepared as described in the Supporting Information) were dispersed
in 10 mL of demineralized water (pH 4.0, adjusted by diluted
hydrochloric acid) in a 50 mL round-bottom flask. After adding 1 mL
of EDC (0.1 M) and 1 mL of NHS (0.1 M), the mixture was stirred
for 12 h at room temperature (RT). Then, the pH of the mixture was
Figure 3. (a) Comparison of the minimal bactericidal concentrations (MBCs) of gentamicin (G) and magnetic nanoparticles with conjugated
gentamicin (MNPs-G), expressed in gentamicin-equivalent concentration against ESKAPE pathogens and E. coli. Data are expressed as mean ±
standard deviation over three separate experiments. Statistical analysis was performed between G and MNPs-G using Student’s two-tailed t test (*p
< 0.05, **p < 0.01, ****p < 0.0001). (b) Viability of human fibroblasts (American Type Culture Collection ATCC-CRL-2014) after 24 h growth
in medium in the presence of different concentrations of G and MNPs-G, as derived from an XTT-conversion assay. Relative viabilities are
expressed as mean ± standard deviation over three separate experiments, while 100% represents XTT conversion in PBS.
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adjusted to 9.0 by adding 0.4 mL of NaOH (0.05 M), and 1 mL of
gentamicin (0.1 M) was added, followed by stirring for another 12 h
at RT. The black particles obtained were magnetically separated and
washed with demineralized water three times in order to remove
unreacted gentamicin molecules. Finally, MNPs-G were dispersed in
phosphate buffered saline (PBS, 5 mM K2HPO4, 5 mM KH2PO4, 150
mM NaCl, pH 7.4) using sonication (Transonic TP 690, ELMA,
Germany, 160 W, 35 kHz) at RT for 30 min.
The size and shape of MNPs-G were determined using trans-
mission electron microscopy (TEM, G-120, Hitachi, Japan). The
conjugation of G to MNP was characterized by Fourier transform
infrared spectroscopy (FTIR, Nicolet-20DXB, US). Spectra were
taken over a wavenumber range from 500 to 4000 cm−1 at a
resolution of 2.0 cm−1. All spectra represent averages from 16
interferograms. Zeta potentials were measured in demineralized water
using a Malvern NanoSizer ZS2000 (UK). Zeta potentials were
measured in triplicate on separately prepared batches of MNPs-G.
Magnetic properties of MNPs-G were measured at RT using a
vibrating sample magnetometer (model 7410, Lake Shore, USA). The
mass content of G in MNPs-G was analyzed using a combination of
thermogravimetric (TA2100 USA, heating rate 10 °C min−1) and
elemental analysis (Vario EL cube, Germany).
Bacterial Strains, Growth Conditions, and Harvesting.
Enterobacter cloacae BS 1037, Staphylococcus aureus ATCC 12600,
Klebsiella pneumonia-1, Acinetobacter baumannii-1, Pseudomonas
aeruginosa PA01, Enterococcus faecalis 1396, and Escherichia coli
ATCC 25922 were grown from stock solutions (7% DMSO, kept at
−80 °C) on blood agar plates at 37 °C for 24 h. For precultures, a
single bacterial colony was transferred into 10 mL of tryptone soy
broth (TSB, OXOID, Basingstoke, UK) and incubated 24 h at 37 °C.
For main cultures, the preculture was transferred into 200 mL of TSB
and incubated for 16 h at 37 °C. Then, bacteria were harvested by
centrifugation (5000g, 5 min, 10 °C) followed by washing twice in
sterile PBS. The bacterial suspension was sonicated (Vibra cell model
375, Sonics and Material Inc., Danbury, CT) three times each for 10 s
Figure 4. (a) Distribution of Rhodamine-B isothiocyanate labeled
MNP-G as a function of the depth in the biofilm (biofilm thicknesses
53 ± 14 μm) for different magnetic-field exposure times, as calculated
from CLSM images (see Figure S1a). Biofilms were exposed to MNP-
G suspensions in PBS (440 μg mL−1) for 3 h and were made green-
fluorescent by staining with SYTO9 in order to distinguish between
bacteria and nanoparticles. (b) Percentage of dead bacteria relative to
the total number of bacteria in an image stack as a function of depth
in the biofilm, as obtained after DEAD/LIVE staining, as calculated
from CLSM images (Figure S1b). (c) Bacterial-killing over the entire
depth of a biofilm (“biofilm-killing efficacy” relative to the total
number of bacteria in a biofilm) as a function of MNPs-G
accumulation in a biofilm. Colors correspond with magnetic-field
exposure times (see panel a). Data are expressed as mean ± standard
deviation over three separate experiments.
Figure 5. Comparison of the depth-dependent killing of S. aureus and
biofilm-killing efficacy of S. aureus ATCC 12600 upon exposure to
gentamicin, MNPs, or MNPs-G in the absence and presence of
optimized 5 min magnetic-field exposure. PBS was included as a
control. Total exposure time to the antimicrobials was 180 min. (a)
Percentage of dead bacteria relative to the total number of bacteria in
an image stack as a function of depth in the biofilm, as obtained after
DEAD/LIVE staining, as calculated from CLSM images (Figure S2).
Superscripts “−” and “+” denote the absence and presence of magnet-
field exposure, respectively. (b) Bacterial-killing over the entire depth
of a staphylococcal biofilm (“biofilm-killing efficacy” relative to the
total number of bacteria in a biofilm). Data are expressed as mean ±
standard deviation over three separate experiments. Statistical analysis
was performed using Student’s two-tailed t test (**p < 0.01, ***p <
0.001).
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with 30 s intervals between each cycle on ice to obtain a suspension
with single bacteria. The bacterial concentrations of the suspension
were adjusted values appropriate for later use, as determined in a
Bürker−Türk counting chamber.
Minimal Bactericidal Concentration (MBC). To determine the
MBCs of different strains, 100 μL of G, MNPs, and MNPs-G (1 mg
mL−1) in PBS were put in a 96-well plate and 100 μL of TSB was
added. Then, solutions were mixed and 2-fold serially diluted. Next,
10 μL of bacterial suspension (1 × 105 bacteria mL−1) was added to
mixed solutions in the 96-well plates. After 24 h incubation at 37 °C,
10 μL was taken out of a well and placed on an agar plate and
incubated for 24 h at 37 °C. The lowest concentration at which no
visible colonies were formed was taken as the MBC value. The
experiment was repeated twice with separate bacterial cultures.
MNP-G Distribution in S. aureus Biofilms. For biofilm
formation, we selected S. aureus ATCC 12600 for further experiments,
as it is a prominent pathogen in many types of infection.27,32 A
staphylococcal suspension (1× 109 bacteria mL−1, 2 mL) was put into
a sterile polystyrene 12-well plate for 2 h at RT in order to allow
bacterial adhesion. Thereafter, the suspension was removed, and the
well was washed three times with sterile PBS, filled with fresh TSB,
and incubated for 24 h at 37 °C.
In order to visualize depth-dependent distribution of MNPs-G after
penetration and accumulation in staphylococcal biofilms, MNPs-G
were first labeled with red-fluorescent Rhodamine-B isothiocyanate
(Sigma-Aldrich, USA). To this end, 10 mg of MNP-G and 1 mg of
Rhodamine-B isothiocyanate were mixed in 10 mL of PBS and stirred
for 8 h in the dark at RT. Then, the suspension was dialyzed for 48 h
in demineralized water to remove unreacted Rhodamine-B
isothiocyanate, while refreshing the water every 12 h. After dialysis,
the Rhodamine-B isothiocyanate labeled MNPs-G were magnetically
separated and resuspended in PBS for later use. Next, 24 h S. aureus
biofilms were washed once with sterile PBS, exposed to 2 mL of red-
fluorescent MNP-G (440 μg mL−1) under a magnetic-field created by
a NdFeB magnet (1 mm thickness and 10 mm in diameter with 1.17−
1.21 T residual magnetism) for different times (0, 1, 2, 5, 10, and 30
min) at 37 °C. After magnetic-field exposure, biofilms were placed in
the incubator again. The total exposure time of the biofilms to MNPs-
G amounted to 180 min, including magnetic-field exposure and
incubation. After incubation, the nanoparticle suspension was
removed and bacteria in the biofilms were stained with green-
fluorescent SYTO9 (Thermo Fisher Scientific, Waltham, MA) for 15
min at RT in the dark. Finally, biofilms were washed once with PBS
and subsequently imaged by CLSM (Leica TCS SP2 Leica, Wetzlar,
Germany) with an HCX APO L40×/0.80 W U-V-1 objective. An
argon ion laser at 488 nm and a green HeNe laser at 543 nm were
used to excite the SYTO9 and Rhodamine-B isothiocyanate, and
fluorescence was collected at 500−540 nm (SYTO9) and 583−688
nm (Rhodamine-B isothiocyanate). CLSM images were acquired
using Leica software, version 2.0.
The presence of Rhodamine-B isothiocyanate labeled MNPs-G in
each image stack of a biofilm or in an entire biofilm (“MNPs-G
accumulation”) was calculated as the ratio of red-fluorescent over
green-fluorescent pixels, either in an image stack or in an entire
biofilm. The distribution of MNPs-G across the thickness of
staphylococcal biofilms was measured in triplicate, using separate
bacterial cultures.
S. aureus Killing in Biofilms. Twenty-four hour S. aureus biofilms
were exposed to MNPs-G (no Rhodamine-B isothiocyanate labeling).
Afterward, they were stained with green-fluorescent SYTO9 and red-
fluorescent propidium iodide (Thermo Fisher Scientific, Waltham,
MA) for 15 min at RT in the dark to label live and dead bacteria,
respectively, in the biofilm. Biofilms were subsequently imaged by
CLSM, and depth-dependent staphylococcal killing or killing over the
entire thickness of a biofilm (“biofilm killing efficacy”) was calculated
using ImageJ as the percentage red-fluorescent over the sum of red-
and green-fluorescent pixels, either in an image stack or in an entire
biofilm, respectively.
In order to compare the biofilm-killing efficacy of MNPs-G after
optimized magnetic-field exposure, 24 h staphylococcal biofilms were
exposed to PBS, G (110 μg mL−1 in PBS, equivalent concentration as
in MNPs-G), MNPs-G or MNPs (440 μg mL−1, in PBS) with
magnetic-field exposure, and MNP-G (440 μg mL−1 in PBS) with and
without magnetic-field for 5 min, while total exposure time to
antimicrobials was 180 min, including magnetic-field exposure and
incubation. The experiment was repeated in triplicate with separate
staphylococcal cultures.
Effects of MNPs-G on Mammalian Cells. The cytotoxicity of
MNP-G and G was evaluated according to a previous method.22
Briefly, human fibroblasts (American Type Culture Collection
ATCC-CRL-2014) were cultured in 96-well plates (5 × 103 cells
per well), filled with 100 μL of cell growth medium (Dulbecco’s
modified Eagle’s medium (DMEM, ThermoFisher Scientific)
supplemented with 10% fetal bovine serum (FBS; Invitrogen)).
Subsequently, 100 μL of MNPs-G or G in cellular growth medium
(concentration range 31.25−500 μg mL−1 in G-weight equivalents)
was added and incubated for 24 h in 5% CO2 at 37 °C. After 24 h, 50
μL of XTT ((2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazo-
lium-5-carboxanilide salt), AppliChem) reagent solution combined
with activation solution (PMS, N-methyl dibenzopyrazine methyl
sulfate, Sigma-Aldrich) was added. After another 4 h at 37 °C,
absorbances A485nm were measured using a spectrophotometer
(Shimadzu, Japan). According to the manufacturer’s instructions,
A690nm was measured and subtracted as a reference control. The
viability of the fibroblasts after material exposure was calculated








relative viability (%) 100%material485nm material690nm
PBS485nm PBS690nm
(1)
Statistics. All comparisons of MBCs and biofilm-killing efficacies
between the different treatments were performed with a two-tailed
Student’s t test, accepting significance at p < 0.05.
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